Open Interest and Volume Dynamics
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply by 2,816 contracts, a 14.46% increase from the previous figure of 19,470 to 22,286. This notable expansion in OI coincided with a robust volume of 43,734 contracts traded, underscoring heightened activity among futures and options traders. The combined futures and options value stood at approximately ₹28,444.26 lakhs, with futures contributing ₹22,465.30 lakhs and options an overwhelming ₹26,985.73 crores in notional value, reflecting the stock’s liquidity and investor interest.
The underlying stock price closed at ₹2,590, having touched an intraday high of ₹2,639, marking a 4.26% rise on the day. This price action, coupled with the OI surge, suggests that market participants are positioning for further upside, supported by the stock’s outperformance relative to its sector and the broader Sensex.
Price Performance and Moving Averages
Mankind Pharma has been on a positive trajectory, gaining 3.09% over the last two consecutive trading sessions. The stock’s 1-day return of 2.34% notably outpaced the Pharmaceuticals & Biotechnology sector’s 0.78% and the Sensex’s 0.57% gains on the same day. Furthermore, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong bullish trend and technical support across multiple timeframes.
Despite this momentum, delivery volumes have seen a slight decline. On 14 July, delivery volume stood at 1.49 lakh shares, down 11.1% against the five-day average, signalling a possible reduction in long-term investor participation. However, the stock remains sufficiently liquid, with a trade size capacity of ₹1.63 crore based on 2% of the five-day average traded value, ensuring ease of entry and exit for active traders.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Market Positioning and Investor Sentiment
The surge in open interest alongside rising prices and volumes suggests that traders are increasingly bullish on Mankind Pharma. The stock’s Mojo Score currently stands at 65.0 with a Mojo Grade of Hold, downgraded from Buy as of 1 July 2026. This adjustment reflects a more cautious stance amid recent volatility, though the mid-cap pharmaceutical company continues to attract interest due to its solid fundamentals and sectoral tailwinds.
Market participants appear to be building fresh positions, possibly anticipating positive catalysts such as robust earnings, new product launches, or favourable regulatory developments. The increase in futures and options activity indicates that both hedgers and speculators are actively engaging with the stock, with directional bets likely skewed towards further appreciation given the technical and volume signals.
Sectoral Context and Comparative Performance
Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma’s outperformance by 1.5% relative to peers highlights its relative strength. The sector has been under pressure due to global supply chain concerns and pricing regulations, but Mankind’s consistent gains and rising open interest suggest it is bucking the trend. This divergence may attract investors seeking exposure to resilient mid-cap pharma stocks with growth potential.
However, the recent downgrade to Hold signals that while the stock remains attractive, investors should monitor valuation levels and broader market conditions closely. The stock’s market capitalisation of ₹1,06,185 crore places it firmly in the mid-cap category, balancing growth prospects with moderate risk.
Is Mankind Pharma Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Implications for Traders and Investors
The pronounced increase in open interest, combined with strong volume and price appreciation, points to a growing conviction among market participants. Traders may interpret this as a signal to initiate or add to long positions, expecting the stock to continue its upward trajectory. The fact that Mankind Pharma is trading above all major moving averages further supports this bullish outlook.
Nevertheless, the dip in delivery volumes suggests some caution among long-term holders, possibly reflecting profit-booking or rotation into other sectors. Investors should weigh these mixed signals carefully, considering both technical momentum and fundamental valuations before committing fresh capital.
Outlook and Conclusion
Mankind Pharma’s recent derivatives market activity highlights a dynamic phase of increased participation and directional bets. While the stock’s Mojo Grade has been revised to Hold, its strong price performance and rising open interest underscore sustained investor interest. The pharmaceutical company remains a key player in the mid-cap space, with potential upside driven by sectoral growth and company-specific developments.
Market watchers should continue to monitor open interest trends, volume patterns, and price action closely to gauge the sustainability of this momentum. For now, Mankind Pharma presents a compelling case for cautious optimism amid a complex market environment.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
